Oncolytic virus-mediated cancer cell lysis (null)

"Cancer cell lysis via viral infection" refers not to a discrete molecular target but rather to the therapeutic strategy known as **oncolytic virotherapy**. In this approach, specially engineered or naturally occurring viruses selectively infect and replicate within cancer cells. The process leads directly to **tumor cell destruction** through several mechanisms: • Direct cytolytic effect from massive production and release of new virions. • Activation of programmed cell death pathways such as apoptosis during viral replication. • Stimulation of an immune response—infected cancer cells present viral peptides via MHC class I molecules, attracting CD8+ T lymphocytes that mediate further killing. • Additional indirect effects include enhanced presentation of tumor-associated antigens, which can stimulate broader anti-tumor immunity. This entry does not correspond to a single molecule, receptor, enzyme, transporter, or other canonical drug target but instead describes an entire therapeutic modality. Therefore it is not considered a valid "therapeutic target" in the conventional sense used for structured pharmacological databases.[1][2]

Other names

Oncolytic virotherapyViral oncolysisCancer cell lysis by oncolytic virusTumor cell lysis via viral infection

- Selective infection and replication of viruses within tumor cells leading to direct lysis[1][2] - Induction of immune-mediated killing of infected cancer cells by CD8+ T cells recognizing viral peptides presented on MHC class I molecules[1] - Activation of apoptosis pathways during viral replication and gene expression[1][2] - Indirect antitumor effects through presentation of tumor-associated antigens and engagement of broader antitumor immunity[1]